Holen Sie sich die Stockscreener-App
3.74
1.11%
0.010
Schlusskurs vom Vortag:
$3.75
Offen:
$3.795
24-Stunden-Volumen:
8,544
Relative Volume:
0.05
Marktkapitalisierung:
$20.35M
Einnahmen:
$15.00M
Nettoeinkommen (Verlust:
$2.71M
KGV:
2.9391
EPS:
1.2725
Netto-Cashflow:
$-2.89M
1W Leistung:
+1.11%
1M Leistung:
-0.74%
6M Leistung:
-16.48%
1J Leistung:
-74.88%
1-Tages-Spanne:
$3.76
$3.8647
1-Wochen-Bereich:
$3.72
$3.8647
52-Wochen-Spanne:
$3.19
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
Firmenname
Neuphoria Therapeutics Inc
Sektor
Branche
Telefon
781-439-5551
Adresse
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
3.765 | 20.27M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
522.11 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.76 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,004.25 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.29 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.67 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | Bestätigt | Maxim Group | Buy |
| 2022-01-10 | Eingeleitet | Berenberg | Buy |
| 2022-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-01-10 | Eingeleitet | Evercore ISI | Outperform |
| 2022-01-10 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Neuphoria Therapeutics Inc Aktie (NEUP) Neueste Nachrichten
MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer’s Drug Trial Under Neuphoria Partnership - Stocktwits
Neuphoria Therapeutics Inc (NASDAQ: NEUP) Share Price, NEUP Stock News, NEUP Share Price & Updates - Kalkine
NEUP Q4'26 Earnings: EPS estimate is (0.56) USD - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 90.9% EPS SurpriseGeographic Revenue Trends - vinanet.vn
Neuphoria Therapeutics (NEUP) Pulls Back to $3.82 as Traders Eye Key Support ZoneIron Condor Alert - dars.gov.et
Neuphoria Therapeutics (NEUP) Pulls Back 1.27% to $3.9, Holds Above Key SupportSocial Sentiment - vinanet.vn
Are CBZ, SAFT, NEUP, TCBK Obtaining Fair Deals for their Shareholders? - tradingview.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Neuphoria Therapeutics (NEUP) Slips to $3.88 as Bulls Defend Key SupportSector ETF Flow - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Lean Cost ManagementEarnings Decline Risk - dars.gov.et
NEUP Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 90.9% EPS Surprise Amid Stock PullbackEarnings Weakness Phase - Vinanet
Scancell merges with Nasdaq shell Neuphoria to fund USD 89m Phase III melanoma trial - allsci.com
Neuphoria Therapeutics (NEUP) Holds Near $3.93 as Biotech Stock Tests Key Technical LevelsStock Analysis - vinanet.vn
Neuphoria Therapeutics (NEUP) Gains 3.55% as Stock Tests Key Resistance Near $4.14Volume Weighted Price - vinanet.vn
Advising Nasdaq-listed Neuphoria Therapeutics Inc. On Its USD250M Merger With AIM-listed Scancell Holdings - Mondaq
Neuphoria Therapeutics Inc. (NEUP) Q2 2026 Earnings: Loss Narrows Sharply, Exceeding ExpectationsEarnings Risk Report - vinanet.vn
Advising Nasdaq-listed Neuphoria Therapeutics Inc. on its USD250M merger with AIM-listed Scancell Holdings - winstontaylor.com
Halper Sadeh LLC is Investigating Whether SAFT, NEUP, NRIM are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Mintz Advises on $39 Million Private Placement Concurrent with Scancell Holdings and Neuphoria Therapeutics’ Merger Transaction - Mintz
Neuphoria Therapeutics Inc (NEUP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NEUP|Neuphoria Therapeutics Inc|Price:3.970|Chg%:+0.330 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neuphoria Therapeutics Inc (NEUP) Income Statement - tradingkey.com
Neuphoria Therapeutics (NEUP) Drops 7%: Key Levels in Focus After Sharp DeclineFibonacci Time Zone - po-news-eg.net
Neuphoria Therapeutics Inc. Revenue Breakdown – NASDAQ:NEUP - TradingView
NEUP|Neuphoria Therapeutics Inc|Price:3.810|Chg%:+0.170 - TradingKey
Neuphoria Therapeutics Inc (NEUP) Cash Flow - TradingKey
Neuphoria Therapeutics Market Sentiment - Benzinga España
NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Monteverde & Associates investigates Neuphoria Therapeutics merger fairness for shareholders. - Pluang
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP) - PR Newswire
Neuphoria Therapeutics (NEUP) Proxy filing Summary - Quartr
Neuphoria Therapeutics to Merge with Scancell Holdings - TipRanks
Neuphoria Therapeutics (Nasdaq: NEUP) to be acquired by Scancell - Stock Titan
Neuphoria Therapeutics to Merge With Scancell; Holders to Receive ADSs Plus CVRs - TradingView
Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing - Yahoo Finance UK
NEUPHORIA THERAPEUTICSSCANCELL EXPECTS TO SECURE UP TO $89 MLN IN FINANCING - Moomoo
Neuphoria Therapeutics Agrees to All-Share Takeover by Scancell - Moomoo
Scancell Holdings plc agreed to acquire Neuphoria Therapeutics Inc. for $34.7 million. - marketscreener.com
Scancell, Neuphoria Therapeutics Agree All-share Merger - Moomoo
Scancell merges with Neuphoria after Merck axes trial; AstraZeneca breast cancer drug approved in EU - Endpoints News
Scancell agrees to buy Neuphoria, combined firm set to list on Nasdaq - marketscreener.com
Scancell And Neuphoria Therapeutics Announce Merger Agreement - TradingView
Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing - The Manila Times
Scancell And Neuphoria Therapeutics Announce Merger Agreement And Financing - TradingView
Scancell to join Nasdaq through Neuphoria merger and $89 million funding package - Proactive financial news
Scancell Holdings Secures £9 Million via UK Share Placing Ahead of Nasdaq Merger with Neuphoria Therapeutics - Kalkine Media
Finanzdaten der Neuphoria Therapeutics Inc-Aktie (NEUP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):